Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacolo...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2021-06, Vol.11 (6), p.499 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 499 |
| container_title | Journal of personalized medicine |
| container_volume | 11 |
| creator | Finotti, Michele Romano, Maurizio Auricchio, Pasquale Scopelliti, Michele Brizzolari, Marco Grossi, Ugo Piccino, Marco Benvenuti, Stefano Morana, Giovanni Cillo, Umberto Zanus, Giacomo |
| description | Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome. |
| doi_str_mv | 10.3390/jpm11060499 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8229090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548402249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-1e5a4d81b3e540e90556941a8cf9d7852d0be42a3b3052e92cdf8230dc9a04c83</originalsourceid><addsrcrecordid>eNpdkU1LHEEQhhuJqKgn_0BDLoGwsT_H6RwCg3GjsJqA67mp7anZnU3P9KS7R_DfZ-JKUOtSXw8v9VKEnHH2RUrDzrdDxzkrmDJmjxwJdqFnSoniw6v6kJymtGVTlFqIgh2QQ6m4MVrqI_J7CXGNmS43GGFoMdEmRHpX3V-f31XzxfevdB5DR_MG6W3w6EYPkVZpQJdpDs_zXxuIHbjgw7p14Cn0Nb0f466pfMbYQ24fMZ2Q_QZ8wtOXfEwe5lfLy-vZ4uePm8tqMXOSF3nGUYOqS76SqBVDw7QujOJQusbUF5OHmq1QCZArybRAI1zdlEKy2hlgypXymHzb6Q7jqsPaYZ8jeDvEtoP4ZAO09u2mbzd2HR5tKYRhhk0Cn14EYvgzYsq2a5ND76HHMCYrtCoVE0KZCf34Dt2GcTLsnylVTpzhE_V5R7kYUorY_D-GM_vvj_bVH-Vfh6CONQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2544884091</pqid></control><display><type>article</type><title>Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Finotti, Michele ; Romano, Maurizio ; Auricchio, Pasquale ; Scopelliti, Michele ; Brizzolari, Marco ; Grossi, Ugo ; Piccino, Marco ; Benvenuti, Stefano ; Morana, Giovanni ; Cillo, Umberto ; Zanus, Giacomo</creator><creatorcontrib>Finotti, Michele ; Romano, Maurizio ; Auricchio, Pasquale ; Scopelliti, Michele ; Brizzolari, Marco ; Grossi, Ugo ; Piccino, Marco ; Benvenuti, Stefano ; Morana, Giovanni ; Cillo, Umberto ; Zanus, Giacomo</creatorcontrib><description>Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm11060499</identifier><identifier>PMID: 34199535</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Apoptosis ; Biopsy ; Diabetes ; Fatty acids ; Fatty liver ; Gastrointestinal surgery ; Inflammation ; Insulin resistance ; Kinases ; Liver diseases ; Liver transplantation ; Metabolic syndrome ; Metabolism ; Obesity ; Pathogenesis ; Permeability ; Population ; Precision medicine ; Review ; Surgery ; Weight control</subject><ispartof>Journal of personalized medicine, 2021-06, Vol.11 (6), p.499</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-1e5a4d81b3e540e90556941a8cf9d7852d0be42a3b3052e92cdf8230dc9a04c83</citedby><cites>FETCH-LOGICAL-c316t-1e5a4d81b3e540e90556941a8cf9d7852d0be42a3b3052e92cdf8230dc9a04c83</cites><orcidid>0000-0001-5489-3009 ; 0000-0003-3144-2963 ; 0000-0001-5372-2873 ; 0000-0002-3659-2429</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229090/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229090/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Finotti, Michele</creatorcontrib><creatorcontrib>Romano, Maurizio</creatorcontrib><creatorcontrib>Auricchio, Pasquale</creatorcontrib><creatorcontrib>Scopelliti, Michele</creatorcontrib><creatorcontrib>Brizzolari, Marco</creatorcontrib><creatorcontrib>Grossi, Ugo</creatorcontrib><creatorcontrib>Piccino, Marco</creatorcontrib><creatorcontrib>Benvenuti, Stefano</creatorcontrib><creatorcontrib>Morana, Giovanni</creatorcontrib><creatorcontrib>Cillo, Umberto</creatorcontrib><creatorcontrib>Zanus, Giacomo</creatorcontrib><title>Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives</title><title>Journal of personalized medicine</title><description>Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome.</description><subject>Apoptosis</subject><subject>Biopsy</subject><subject>Diabetes</subject><subject>Fatty acids</subject><subject>Fatty liver</subject><subject>Gastrointestinal surgery</subject><subject>Inflammation</subject><subject>Insulin resistance</subject><subject>Kinases</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Metabolic syndrome</subject><subject>Metabolism</subject><subject>Obesity</subject><subject>Pathogenesis</subject><subject>Permeability</subject><subject>Population</subject><subject>Precision medicine</subject><subject>Review</subject><subject>Surgery</subject><subject>Weight control</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1LHEEQhhuJqKgn_0BDLoGwsT_H6RwCg3GjsJqA67mp7anZnU3P9KS7R_DfZ-JKUOtSXw8v9VKEnHH2RUrDzrdDxzkrmDJmjxwJdqFnSoniw6v6kJymtGVTlFqIgh2QQ6m4MVrqI_J7CXGNmS43GGFoMdEmRHpX3V-f31XzxfevdB5DR_MG6W3w6EYPkVZpQJdpDs_zXxuIHbjgw7p14Cn0Nb0f466pfMbYQ24fMZ2Q_QZ8wtOXfEwe5lfLy-vZ4uePm8tqMXOSF3nGUYOqS76SqBVDw7QujOJQusbUF5OHmq1QCZArybRAI1zdlEKy2hlgypXymHzb6Q7jqsPaYZ8jeDvEtoP4ZAO09u2mbzd2HR5tKYRhhk0Cn14EYvgzYsq2a5ND76HHMCYrtCoVE0KZCf34Dt2GcTLsnylVTpzhE_V5R7kYUorY_D-GM_vvj_bVH-Vfh6CONQ</recordid><startdate>20210602</startdate><enddate>20210602</enddate><creator>Finotti, Michele</creator><creator>Romano, Maurizio</creator><creator>Auricchio, Pasquale</creator><creator>Scopelliti, Michele</creator><creator>Brizzolari, Marco</creator><creator>Grossi, Ugo</creator><creator>Piccino, Marco</creator><creator>Benvenuti, Stefano</creator><creator>Morana, Giovanni</creator><creator>Cillo, Umberto</creator><creator>Zanus, Giacomo</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5489-3009</orcidid><orcidid>https://orcid.org/0000-0003-3144-2963</orcidid><orcidid>https://orcid.org/0000-0001-5372-2873</orcidid><orcidid>https://orcid.org/0000-0002-3659-2429</orcidid></search><sort><creationdate>20210602</creationdate><title>Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives</title><author>Finotti, Michele ; Romano, Maurizio ; Auricchio, Pasquale ; Scopelliti, Michele ; Brizzolari, Marco ; Grossi, Ugo ; Piccino, Marco ; Benvenuti, Stefano ; Morana, Giovanni ; Cillo, Umberto ; Zanus, Giacomo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-1e5a4d81b3e540e90556941a8cf9d7852d0be42a3b3052e92cdf8230dc9a04c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Apoptosis</topic><topic>Biopsy</topic><topic>Diabetes</topic><topic>Fatty acids</topic><topic>Fatty liver</topic><topic>Gastrointestinal surgery</topic><topic>Inflammation</topic><topic>Insulin resistance</topic><topic>Kinases</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Metabolic syndrome</topic><topic>Metabolism</topic><topic>Obesity</topic><topic>Pathogenesis</topic><topic>Permeability</topic><topic>Population</topic><topic>Precision medicine</topic><topic>Review</topic><topic>Surgery</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Finotti, Michele</creatorcontrib><creatorcontrib>Romano, Maurizio</creatorcontrib><creatorcontrib>Auricchio, Pasquale</creatorcontrib><creatorcontrib>Scopelliti, Michele</creatorcontrib><creatorcontrib>Brizzolari, Marco</creatorcontrib><creatorcontrib>Grossi, Ugo</creatorcontrib><creatorcontrib>Piccino, Marco</creatorcontrib><creatorcontrib>Benvenuti, Stefano</creatorcontrib><creatorcontrib>Morana, Giovanni</creatorcontrib><creatorcontrib>Cillo, Umberto</creatorcontrib><creatorcontrib>Zanus, Giacomo</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Finotti, Michele</au><au>Romano, Maurizio</au><au>Auricchio, Pasquale</au><au>Scopelliti, Michele</au><au>Brizzolari, Marco</au><au>Grossi, Ugo</au><au>Piccino, Marco</au><au>Benvenuti, Stefano</au><au>Morana, Giovanni</au><au>Cillo, Umberto</au><au>Zanus, Giacomo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives</atitle><jtitle>Journal of personalized medicine</jtitle><date>2021-06-02</date><risdate>2021</risdate><volume>11</volume><issue>6</issue><spage>499</spage><pages>499-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34199535</pmid><doi>10.3390/jpm11060499</doi><orcidid>https://orcid.org/0000-0001-5489-3009</orcidid><orcidid>https://orcid.org/0000-0003-3144-2963</orcidid><orcidid>https://orcid.org/0000-0001-5372-2873</orcidid><orcidid>https://orcid.org/0000-0002-3659-2429</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2021-06, Vol.11 (6), p.499 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8229090 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Apoptosis Biopsy Diabetes Fatty acids Fatty liver Gastrointestinal surgery Inflammation Insulin resistance Kinases Liver diseases Liver transplantation Metabolic syndrome Metabolism Obesity Pathogenesis Permeability Population Precision medicine Review Surgery Weight control |
| title | Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T11%3A32%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Target%20Therapies%20for%20NASH/NAFLD:%20From%20the%20Molecular%20Aspect%20to%20the%20Pharmacological%20and%20Surgical%20Alternatives&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Finotti,%20Michele&rft.date=2021-06-02&rft.volume=11&rft.issue=6&rft.spage=499&rft.pages=499-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm11060499&rft_dat=%3Cproquest_pubme%3E2548402249%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2544884091&rft_id=info:pmid/34199535&rfr_iscdi=true |